Forkhead transcription factors of the O class (FOXOs) are important targets of the phosphatidylinositol 3-kinase/Akt pathway, and are key regulators of the cell cycle, apoptosis and response to oxidative stress. FOXOs have been shown to have tumour suppressor function and are important for stem cell maintenance. We have performed a detailed analysis of the transcriptional programme induced in response to Forkhead-box protein O3a (FOXO3a) activation. We observed that FOXO3a activation results in the repression of a large number of nuclear-encoded genes with mitochondrial function. Repression of these genes was mediated by FOXO3a-dependent inhibition of c-Myc. FOXO3a activation also caused a reduction in mitochondrial DNA copy number, expression of mitochondrial proteins, respiratory complexes and mitochondrial respiratory activity. FOXO3a has been previously implicated in the detoxification of reactive oxygen species (ROS) through induction of manganese-containing superoxide dismutase (SOD2). We observed that reduction in ROS levels following FOXO3a activation was independent of SOD2, but required c-Myc inhibition. Hypoxia increases ROS production from the mitochondria, which is required for stabilisation of the hypoxia-inducible factor-1a (HIF-1a). FOXO3a activation blocked the hypoxia-dependent increase in ROS and prevented HIF-1a stabilisation. Our data suggest that FOXO factors regulate mitochondrial activity through inhibition of c-Myc function and alter the hypoxia response. 4 FOXO factors regulate the expression of genes involved in the inhibition of cell cycle progression and induction of apoptosis.
Forkhead transcription factor of the O class (FOXO) proteins form a subgroup of the larger family of Forkhead-boxcontaining transcription factors, which are identified by the winged-helix structure of their DNA binding domain. 1 The mammalian genome encodes four different FOXO proteins (FOXO1, FOXO3a, FOXO4 and FOXO6). Phosphorylation of FOXO proteins by Akt results in their exclusion from the nucleus and enhanced degradation. 2, 3 Importantly, FOXO factors have emerged as tumour suppressors in several systems. 4 FOXO factors regulate the expression of genes involved in the inhibition of cell cycle progression and induction of apoptosis. 5 FOXO also regulates detoxification of reactive oxygen species (ROS) through upregulation of mitochondrial superoxide dismutase (SOD2). 6 Mitochondria are central hubs for cellular bioenergetics and are an important source of ROS within mammalian cells. ROS are produced by the respiratory complexes located in the inner mitochondrial membrane. Mitochondrial ROS can cause oxidative damage to the mitochondrial DNA (mtDNA), proteins and lipids, but are also involved in signalling from the mitochondria to the cytoplasm. The regulation of mitochondrial function is crucial for the survival of both normal and cancer cells. 7 The mitochondrial genome encodes only 13 proteins. The majority of proteins required for the maintenance of the structure and function of mitochondria are nuclear encoded. The expression of these genes is regulated by a network of transcription factors, including the nuclear respiratory factors 1 and 2 (NRF1 and NRF2) and the oestrogen-related receptor-a (ERRa). These are bound to and activated by cofactors, peroxisome proliferator-activated receptor gamma co-activator-1a and 1b (PGC1a and PGC1b) and PGC-related 1 (PRC). 8 In addition, the transcription factor c-Myc emerged as an important regulator of mitochondrial gene expression. 9, 10 Interestingly, the hypoxia-inducible factor-1a (HIF-1a) downregulates mitochondrial biogenesis via inhibiting c-Myc as part of the cellular adaptation to hypoxia. 10 We have shown previously that FOXO3a induces the expression of c-Myc antagonists of the Mad/Mxd family. In particular, FOXO3a drives the expression of Mxi1 by binding to Daf-16-binding elements within the first intron of the gene. 11 Induction of Mad/Mxd proteins is required for efficient inhibition of c-Myc-dependent gene expression and cell cycle arrest following FOXO3a activation by inhibiting c-Myc. 11 Here, we present a comprehensive analysis of the transcriptional response to FOXO3a, which revealed the repression of a large number of nuclear-encoded mitochondrial genes through the inhibition of c-Myc function. We show that through this signalling arm, FOXO3a activation alters mitochondrial activity and reduces cellular ROS production, independent of SOD2 activation. Regulation of mitochondrial structure and function could be an important role of FOXO factors in regulating ROS production and affect cellular adaptation to hypoxia.
Results

FOXO3a
activation causes downregulation of mitochondrial gene expression. In order to characterise the complete transcriptional response to FOXO3a activation, we used DLD-1 colon cancer cells expressing a 4-hydroxytamoxifen (4-OHT)-inducible version of FOXO3a, in which the three Akt phosphorylation sites have been replaced with alanine (FOXO3a.A3-ER), thereby rendering its activity completely dependent on the presence of agonist. This cell line (termed DL23) has previously been used to determine the role of FOXO3a in cell cycle regulation. 12 Using human exon microarrays, we identified over 2700 genes with significantly altered expression levels following FOXO3a activation, including many known FOXO target genes (Supplementary Table 1 ). To characterise these gene expression changes, we compared our results with publicly available gene sets (Molecular Signature Database, Broad Institute) using gene set enrichment analysis (GSEA). Among the most significantly enriched gene sets were signatures previously associated with mitochondrial functions, including a curated collection of genes with mitochondrial function (HUMAN_MITODB_6_2002), PGC target genes, tricarboxylic acid (TCA) cycle enzymes and genes involved in oxidative phosphorylation (Figure 1a and b). These gene sets show a strong association with genes downregulated following FOXO activation, as indicated by the negative enrichment score. As predicted by the GSEA, most genes within the HUMAN_MITODB_ 6_2002 gene set are downregulated following FOXO3a activation, but are unaffected by 4-OHT treatment in the parental line (DLD-1; Figure 1c) . Among the upregulated genes within this gene set are SOD2 and pyruvate dehydrogenase kinase 4 (PDK4), two previously identified FOXO target genes. 6, 13 We next investigated whether FOXO3a altered the expression of members of the PGC family or the mitochondrial transcription factors A, B1 and B2 (TFAM, TFB1M and TFB2M), which regulate the expression of mitochondriaencoded genes.
8 FOXO3a activation resulted in rapid and pronounced downregulation of PGC1b and PRC expression (Figure 1d ). Furthermore, expression of TFAM, TFB1M and TFB2M was significantly reduced upon FOXO3a activation, albeit with slower kinetics (Figure 1d ). PGC1a expression was not detected in DL23 cells (data not shown). Activation of endogenous FOXOs by treatment of DLD-1 cells with the phosphatidylinositol 3-kinase inhibitors, LY-294002 or PI-103, also decreased expression of PGC1b, PRC and TFAM, whereas direct FOXO target genes, SOD2 and Mxi1, were upregulated (Supplementary Figure S1) .
We then investigated whether PGC1b or PRC are involved in the regulation of mitochondrial gene expression by FOXO3a. Silencing of PGC1b or PRC did not alter TFAM expression in the presence or absence of FOXO3a activation (Figure 1e ). Furthermore, silencing of NRF1, ERRa or GABPA (DNA-binding subunit of NRF2) did not affect inhibition of TFAM expression following FOXO3a activation (Figure 1e ). Efficient ablation of genes by small interfering RNA (siRNA) was confirmed by qRT-PCR (Figure 1f) . A reporter construct carrying proximal sequences from the promoter of the human TFAM gene, containing binding sites for NRF1, NRF2 and SP1, 14 was unaffected by FOXO3a activation (Supplementary Figure S2b ). Together, these results indicate that the repression of mitochondrial gene expression by FOXO3a is independent of the PGC/NRF regulatory network.
The Mad/Mxd family of transcriptional repressors contributes to the inhibition of mitochondrial genes by FOXO3a. c-Myc induces the expression of a number of mitochondrial genes, including TFAM, by directly binding to their promoters. 9 We compared the functional classification of FOXO3a-regulated mitochondrial genes with published mitochondrial target genes of c-Myc. 9 Three functional categories are overrepresented in the Myc-regulated gene expression signature and the genes downregulated following FOXO3a activation: mitochondrial protein synthesis, mitochondrial transporters and mtDNA maintenance and transcription (Figure 2a) . Indeed, the majority of c-Mycregulated mitochondrial genes identified in the study by Li et al. were repressed following FOXO3a activation in our data set (Figure 2b ).
We have shown that FOXO3a inhibits c-Myc-dependent gene expression by inducing the expression of members of the Mad/Mxd family of c-Myc antagonists. 11 We therefore asked whether induction of these antagonists is also involved in the inhibition of mitochondrial genes by FOXO3a. Silencing of Mxi1 alone had no effect on the expression of a panel of mitochondrial genes. However, combined silencing of all four Mad/Mxd genes (Mad1, Mxi1, Mad3 and Mad4) resulted in a partial yet significant inhibition of FOXO3a-dependent downregulation (Figure 2c and d) . This indicates that induction of these factors does indeed contribute to inhibition of mitochondrial gene expression by FOXO3a.
FOXO3a inhibits mitochondrial gene expression by reducing c-Myc stability. FOXO3a activation results in a considerable reduction of c-Myc protein levels (Delpuech et al 11 and Figure 3c , lanes 1 and 2). We therefore investigated whether ablation of c-Myc induces changes in the expression of mitochondrial genes. The majority of genes in a panel representative of the functional categories identified in Figure 2a were downregulated following silencing of c-Myc in parental DLD-1 cells (Figure 3a) . We then asked whether restoring c-Myc protein levels prevents the FOXO3a-dependent downregulation of mitochondrial genes. Expression of c-Myc in DL23 cells using a retroviral vector restored c-Myc protein to similar levels observed before FOXO3a activation ( Figure 3c ) and did not alter the induction of direct transcriptional targets, such as Mxi1, by FOXO3a (Figure 3d ). However, c-Myc expression fully restored the expression of most mitochondrial genes within this panel in the presence of active FOXO3a, except IDH2, indicating that inhibition of c-Myc is vital for the inhibition of these genes ( Figure 3e ).
As loss of c-Myc protein following FOXO3a activation was not associated with a significant reduction in c-Myc mRNA levels (Supplementary Figure S3) , we examined the effect of FOXO3a activation on c-Myc protein stability. c-Myc is regulated by phosphorylation-dependent ubiquitination and proteasomal degradation. 15 Addition of the proteasome inhibitor MG132 prevented the loss of c-Myc protein following FOXO3a activation (Figure 4a ). Furthermore, FOXO3a activation decreased the stability of c-Myc protein in the presence of cycloheximide (Figure 4b and c) . Recognition of c-Myc by the Fbw7 ubiquitin ligase requires phosphorylation of threonine 58 (T58) by glycogen synthase kinase 3 (GSK3), 16, 17 as well as a priming phosphorylation on serine 62 (S62). 18 We used antibodies raised against a c-Mycderived peptide carrying phosphates on T58 and S62, which detects c-Myc protein phosphorylated at T58 under the conditions used by us. 19 FOXO3a activation increased phosphorylation of c-Myc at T58 (Figure 4d, lanes 1 and 2) . not affected by FOXO3a activation, suggesting that FOXO3a does not alter GSK3 activity itself, but may instead regulate the priming phosphorylation.
FOXO3a activation alters mitochondrial function. Many cancer cell lines show defects in their respiratory activity. 21 We therefore used a non-malignant, immortalised epithelial cell line (RPE-hTERT) to investigate the effect of FOXO3a on mitochondrial function. FOXO3a.A3-ER was introduced into these cells by retroviral transduction to generate a stable cell line (termed RPE-F). Activation of FOXO3a following 4-OHT treatment was confirmed by analysing the induction of p27 KIP1 and Mxi1-SRa (data not shown). FOXO3a activation resulted in substantial downregulation of mitochondrial genes in these cells (Figure 5a ). We next investigated whether FOXO3a activation induced changes in the levels of mitochondrial proteins, mtDNA copy number and mitochondrial mass. FOXO3a activation lowered the expression of Tomm20, a mitochondrial transporter, and cytochrome c oxidase 1 (COX1), a mitochondria-encoded gene (Figure 5b ). FOXO3a activation also resulted in a moderate but significant reduction of the ratio of mitochondrial to nuclear DNA, indicative of a reduction in mtDNA copy number (Figure 5c ). Silencing of TFAM, which regulates mtDNA replication, caused a 50% reduction in the mtDNA copy number (Figure 5d ). The reduction of mtDNA copy number following FOXO3a activation is consistent with the TFAM downregulation observed (Figure 5a ). We also used Mitotracker green (MTG) staining to examine effects on mitochondrial mass. Although a substantial increase in total MTG fluorescence was detected following resveratrol treatment, a known activator of mitochondrial biogenesis, 22 no significant change was observed in response to FOXO3a activation in these cells (Supplementary Figure S4) . Confocal microscopy of MTG-stained cells revealed that FOXO3a activation altered mitochondrial appearance from a filamentous network to more punctate structures (Figure 5e ). The total area of MTG fluorescence was reduced (Figure 5f ), suggesting that FOXO3a activation causes a contraction of the mitochondrial network.
We next assessed mitochondrial respiratory activity by determining oxygen consumption rates (OCRs). FOXO3a activation resulted in a significant decrease in OCR (Figure 5f ). Although FOXO3a activation increases PDK4 expression (Figure 5i, left part) , the FOXO3a-dependent decrease in OCR was still observed when cells were incubated with dichloroacetate (DCA), an inhibitor of PDK (Figure 5g ). This suggests that inhibition of mitochondrial activity by FOXO3a is at least in part independent of PDK4. Furthermore, FOXO3a activation caused a strong reduction in the OCR in the presence of the uncoupling agent FCCP indicative of lower mitochondrial maximal capacity, providing additional evidence for a PDK4-independent effect on mitochondrial activity (Figure 5h, left part) . FOXO3a activation also decreased the amounts of mitochondrial respiratory complexes (Figure 5j, lanes 1 and 2) .
We next investigated the role of c-Myc in the regulation of mitochondrial activity by FOXO3a. Expression of c-Myc in RPE-F cells caused a moderate increase in basal OCR, but this was still reduced by FOXO3a activation (Figure 5h , left part). This reduction could be due to the enhanced expression of PDK4 observed in these cells following 4-OHT treatment (Figure 5i ). c-Myc expression resulted in a substantial increase in mitochondrial capacity (FCCP-induced OCR) and blocked the ability of FOXO3a to reduce capacity (Figure 5h ). c-Myc also increased the amount of mitochondrial respiratory complexes both in the presence and absence of FOXO3a activity (Figure 5i ).
Mitochondrial fission has been shown to be involved in mitochondrial remodelling during FOXO3a-dependent muscle atrophy. 23 However, we did not observe induction of the fission regulators FIS1 or DRP1 upon FOXO3a activation Figure S5a) . Furthermore, inhibition of mitochondrial fission using the DRP1 inhibitor Mdivi-1 did not prevent the downregulation of OCR by FOXO3a (Supplementary Figure S5b ). Although we cannot exclude that mitochondrial fission contributes to the morphological changes induced by FOXO3a activation, it seems unlikely that it is responsible for the alterations in mitochondrial activity.
FOXO3a activation reduces ROS levels independent of SOD2. The mitochondrial respiratory chain is a major source of cellular ROS. Superoxide is produced by complexes I and III and is released into the mitochondrial matrix, where it can be converted into hydrogen peroxide and subsequently into water by SOD2 and catalase (CAT). Complex III can also release superoxide into the intermembrane space, thereby affecting cytoplasmic signalling processes. 24 We found that FOXO3a activation caused a significant reduction in ROS levels in RPE-F cells (Figure 6a ). FOXO3a increases resistance to oxidative stress caused by glucose depletion in quiescent fibroblasts by inducing the expression of SOD2. 6 Although silencing of SOD2 significantly increased ROS levels in RPE-F cells, FOXO3a activation was still able to cause a strong reduction in ROS levels in the absence of SOD2 (Figures 6a) . Furthermore, inhibition of SOD2 using the inhibitor diethyldithiocarbamate (DETC) did not prevent the reduction in ROS levels following FOXO3a activation (Figure 6b ). CAT expression was not induced by FOXO3a activation in these cells (Figure 6c ). 
Importantly, expression of c-Myc in RPE-F cells prevented the downregulation of ROS levels following FOXO3a activation (Figure 6d ). In the c-Myc-expressing cells, FOXO3a still induces SOD2, although SOD2 itself is upregulated by c-Myc expression (Figure 6e ). Together, these data indicate that FOXO3a inhibits ROS levels through c-Myc inhibition rather than through SOD2 upregulation.
Endogenous FOXO3a affects expression of mitochondrial genes in hypoxic cells. Inhibition of mitochondrial biogenesis is an important metabolic adaptation to hypoxia. Indeed, apart from TFB1M, all mitochondrial FOXO3a target genes tested were downregulated after 24 h of hypoxia (o0.5% oxygen) in parental RPE-hTERT cells (Figure 7a ). It has been reported that FOXO3a is induced in response to hypoxic stress. 25 However, we did not observe significant changes in FOXO1 or FOXO3a mRNA levels in hypoxia in RPE-hTERT cells (Figure 7b ). Although silencing of FOXO1 or FOXO3a increased expression of all mitochondrial genes in normoxic cells, hypoxia-dependent downregulation was mainly affected by depletion of FOXO3a (Figure 7c ). In contrast, silencing of FOXO1 only affected the expression of PGC1b and TFAM in hypoxic cells (Figure 7c ), suggesting that FOXO3a is responsible for the inhibition of mitochondrial genes by hypoxia.
FOXO factors regulate ROS and HIF-1a levels in hypoxia. Mitochondrial ROS production is increased in hypoxia, and ROS produced through the electron transport chain have a key role in the adaptation to hypoxia. 26 We found that FOXO3a activation blocks the increase in ROS levels in cells exposed to hypoxia (Figure 8a ). This activity is independent of SOD2 induction, as silencing of SOD2 caused a threefold increase in ROS levels in hypoxic cells but did not affect the ability of FOXO3a to reduce ROS levels in either normoxia or hypoxia (Figure 8b) .
Several studies have shown that ROS produced by mitochondrial complex III is required for stabilisation of HIF-1a in hypoxia. [27] [28] [29] [30] Complex III-derived ROS can be released into the cytoplasm and putatively decrease the activity of prolyl hydroxylases (PHDs), thereby preventing degradation of HIF-1a by the Von Hippel Lindau (VHL) protein. 26 We therefore investigated the effect of FOXO3a activation on HIF-1a stability in hypoxic RPE-F and DL23 cells. Figures 8c and  d show that FOXO3a activation abolished HIF-1a induction by hypoxia. Interestingly, this activity of FOXO3a is dependent on inhibition of c-Myc, as re-expression of c-Myc restored HIF-1a expression in hypoxic cells (Figure 8c and d, lanes 7 and 8) .
Surprisingly, FOXO3a activation had differential effects on HIF-1a mRNA in the cell lines studied. FOXO3a reduced HIF-1a mRNA levels in RPE-F cells, but this was not observed in DL23 cells (Figure 8e and Supplementary Figure S6) . Owing to the reduction in HIF1-a mRNA following FOXO3a activation in RPE-F cells, inhibition of PHDs or silencing of VHL did not rescue HIF-1a protein in these cells (Supplementary Figure S7) . However, downregulation of HIF-1a mRNA in RPE-F cells was not dependent on c-Myc inhibition, as this was not affected by c-Myc re-expression (Figure 8e ). The ability of c-Myc to rescue HIF-1a protein levels following FOXO3a activation without affecting its mRNA suggests that FOXO3a regulates HIF-1a protein stability through c-Myc inhibition. Indeed, in DL23 cells where there is no effect of FOXO3a on HIF-1a mRNA, proteasome inhibition blocked the downregulation of HIF-1a protein levels (Figure 8f) . Furthermore, increasing ROS levels with an exogenous oxidant tert-butyl hydroperoxide (TBP) rescued the loss of HIF-1a protein levels following FOXO3a activation under hypoxia in a dosedependent manner (Figure 8g ).
Our data suggest that FOXO3a can reduce ROS levels in hypoxia independent of SOD2 induction. Furthermore, FOXO3a activation reduces HIF-1a accumulation in hypoxia and this is overcome by re-expression of c-Myc.
Discussion
In this study, we have analysed the global transcriptional response to FOXO3a activation and identified a novel connection between FOXO3a and mitochondrial function. Surprisingly, repression of mitochondrial target genes by FOXO3a is independent of the established transcriptional networks involving NRF1, NRF2 or ERRa. Insulin-like growth factor has been shown to induce expression of nuclearencoded mitochondrial genes in Schwann cells through activation of ERRa. 31 We found that downregulation of mitochondrial gene expression by FOXO3a was mediated through c-Myc inhibition. c-Myc has a well-established role in regulating mitochondrial gene expression. 9 It has been suggested that activation of mitochondrial gene expression by c-Myc involves the induction of PGC1b. 10 However, it is likely that c-Myc can also directly regulate a number of nuclear-encoded mitochondrial genes by binding to E-boxes embedded within the NRF1-DNA-binding motif. 32 Several previous studies have indicated that FOXO factors can antagonise c-Myc function on multiple levels. 11, [33] [34] [35] We show here that FOXO3a inhibits mitochondrial gene expression by inducing expression of Mad/Mxd proteins and by modulating c-Myc protein stability. The reduction in c-Myc stability following FOXO3a activation could be an acute mechanism to rapidly downregulate the expression of mitochondrial genes, whereas the induction of Mxd/Mxd proteins may ensure their sustained inhibition.
Consistent with inhibition of mitochondrial gene expression, FOXO3a activation reduced mtDNA copy number, decreased expression of mitochondrial proteins and lowered the levels of respiratory complexes. FOXO3a also reduced respiration both in coupled and uncoupled conditions. It is likely that PDK4 induction contributes to the inhibition of basal oxygen consumption by blocking entry of pyruvate into the TCA cycle. However, FOXO3a activation reduced oxygen consumption in the presence of DCA, an inhibitor of PDK4. Interestingly, re-expression of c-Myc did not alter the effect of FOXO3a activation on basal oxygen consumption but prevented the reduction in mitochondrial capacity. Thus, FOXO3a has multiple effects on mitochondrial function; it reduces mitochondrial capacity through inhibition of c-Myc and lowers the entry of pyruvate into the mitochondrial metabolism by induction of PDK4 (Figure 8h) .
We found that the reduction in ROS levels by FOXO3a activation was independent of SOD2 but was reversed by reexpression of c-Myc. It has been shown that c-Myc regulates glycolysis and oxidative phosphorylation to enable rapid cell cycle entry, and absence of c-Myc causes mitochondrial dysfunctions. 36 The opposing effects of FOXO factors and c-Myc on mitochondrial metabolism and gene expression are likely to represent a switch between two distinct cellular states. c-Myc promotes mitochondrial production of energy and metabolites for macromolecule synthesis during cell cycle entry, whereas FOXO factors reduce mitochondrial output to prevent excess ROS production. Limiting mitochondrial ROS production is particularly important in conditions of oxygen deprivation. However, ROS can also act as important mediators of cellular signalling. In particular, mitochondriaderived ROS is required for the accumulation of HIF-1a in hypoxia. 27 We found that FOXO3a activation prevented the increase in ROS levels in hypoxic cells independent of SOD2 expression. Interestingly, FOXO3a activation prevented hypoxic accumulation of HIF-1a, which was restored by re-expression of c-Myc. Previous studies showed that FOXO3a is induced in hypoxia and can inhibit HIF1-a-dependent gene expression by directly binding to HIF-1a 37 or through induction of the transcriptional cofactor CITED2. 25 However, studies in neural stem cells from foxo3aÀ/À mice revealed that FOXO3a is required for the expression of hypoxia-dependent genes. 38 Decreasing mitochondrial function is an important role of HIF-1a in the response to hypoxia. By regulating mitochondrial gene expression, FOXO3a may replace some of the function of HIF-1a in the adaptation to hypoxia.
In conclusion, our study reveals a novel role of FOXO factors in regulating mitochondrial activity through repression of c-Myc function. Mitochondrial ROS signalling is known to contribute to Ras-dependent transformation and tumourigenesis. 39 The regulation of mitochondrial gene expression and mitochondrial activity could therefore be important in the role of FOXO factors as tumour suppressors.
Materials and Methods
Plasmids and reagents. pBABEpuro-HA-FKHR-L1.A3-ER has been described previously.
12 pWZL-Blast-c-Myc was constructed by inserting the cDNA of c-Myc into pWLZ-Blast. pBABE-Blast was obtained from M Murillo (CRUK LRI, London, UK). pGL3-basic mtTFA-luc WT was kindly supplied by Professor R Scarpulla (Northwestern Medical School, Chicago, IL, USA).
MG132 and PI-103 were obtained from Calbiochem/Merck (Darmstadt, Germany). LY-294002 was from Cell Signaling Technology (Danvers, MA, USA). Cycloheximide, the GSK3 inhibitor SB216763, resveratrol, FCCP, DMOG, 4-OHT, the DRP1 inhibitor Mdivi-1, the SOD2 inhibitor sodium DETC and TBP were obtained from Sigma (Poole, UK).
Cell culture. DL23 12 and parental DLD-1 cells were grown in RPMI 1640 supplemented with 10% fetal calf serum (FCS). 4-OHT was dissolved in ethanol and used at a final concentration of 100 nM. RPE-hTERT cells (Clontech, Mountain View, CA, USA) and derivatives were grown in DMEM/HAMS F12 (1 : 1) medium supplemented with 10% FCS, glutamine and sodium bicarbonate. pBABEpuro-HA-FKHR-L1.A3-ER (FOXO3a.A3-ER) retroviruses were packaged in Phoenix cells and used to infect RPE-hTERT cells. Infected cells were selected using puromycin, and clone F12 was chosen for further study.
To create c-Myc-expressing cells, pWZL-Blast-c-Myc retroviruses were packaged in Phoenix cells and used to infect DL23 or RPE-hTERT.FOXO3a.A3-ER cells. Infected cells were selected using blasticidin. All experiments were performed using early passages.
Hypoxia was generated using an InVivo 2 500 hypoxic work station (Ruskinn, Bridgend, UK).
Immunoblotting. Cells were lysed in Triton buffer (1% Triton X-100, 50 mM Tris, pH 7.5, 300 mM NaCl, 1 mM EGTA and protease inhibitor cocktail, Roche (Basel, Switzerland)). Plates were incubated for 20 min on ice, and lysates were cleared by centrifugation. Lysates were separated by SDS-polyacrylamide gel electrophoresis and transferred onto an Immobilon membrane (Millipore, Billerica, MA, USA). Proteins were detected by immunoblotting with ECL detection. The following antibodies were used: anti-c-Myc 9E10 (CRT, London, UK), anti-phosphoc-Myc (Cell Signaling Technology), anti-GSK3a/b (Cell Signaling Technology), antib-catenin (Cell Signaling Technology), anti-COX1 antibody (Invitrogen, Carlsbad, CA, USA), anti-Tomm20 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), MitoProfile Total OXPHOS Human WB Antibody Cocktail (Mitosciences, Eugene, OR, USA), anti-HIF-1a (BD Biosciences, Franklin Lakes, NJ, USA), anti-btubulin-horseradish peroxidase (Abcam, Cambridge, UK) and anti-b-actinhorseradish peroxidase (Abcam). Secondary antibodies used are donkey antirabbit IgG-horseradish peroxidase (GE Healthcare, Little Chalfont, UK) and sheep anti-mouse IgG-horseradish peroxidase (GE Healthcare). The intensities of immunoblot bands from three independent experiments were quantified using Image J software (National Institutes of Health, Bethesda, MD, USA) and normalised to the intensities of the loading control from each experiment. mtDNA ratio. Total DNA was extracted using DNeasy kits (Qiagen). qPCR was performed to determine the relative amounts of an amplicon within a mitochondrial gene (cytochrome b) to that of a nuclear gene (b-actin). The primer sequences used were: cytochrome b: 5 0 -GCGTCCTTGCCCTATTACTATC-3 0 and 3 0 -CTTAC TGGTTGTCCTCCGATTC-5 0 ; b-actin: 5 0 -ACCCACACTGTGCCCATCTAC-3 0 ; and 3 0 -TCGGTGAGGATCTTCATGAGGTA-5 0 .
Mitotracker staining for flow cytometry. RPE-hTERT.FOXO3a.A3.ER cells were stimulated with 4-OHT for 48 h before fixation with 3.7% formaldehyde for 15 min at 37 1C. Cells were incubated with 100 nM MTG in PBS (Molecular Probes/ Invitrogen, Carlsbad, CA, USA) for 10 min at room temperature according to the manufacturer's instructions for staining of fixed cells. Incubation with MTG was carried out after fixation to determine mitochondrial mass independent of mitochondrial activity. Cells were washed twice in PBS and analysed with an
